Dr. Reddy's Q4 profit surges 22% YoY to ₹1,594 crore, board recommends dividend; Check details

Dr Reddy's Laboratories on Friday, May 9, reported a 22% year-on-year (YoY) surge in its net profit to ₹1,593.9 crore for the fourth quarter of the 2024-25 fiscal year (Q4 FY25). It clocked a net profit of ₹1,307 crore in the corresponding period last year.

The pharmaceutical's revenue from operations surged 8.6% YoY to ₹8,506 crore in the quarter under review, in contrast to ₹7,830 crore registered in the year-ago period.

Dr Reddy's generated ₹1,167.5 crore in revenue from the pharmaceutical services and active ingredients segment, up 1.29% YoY. Further, its global generics business grew 23.16% YoY to ₹7,536.5 crore in revenue. However, its revenue from other segments fell 90.70% YoY to ₹13.2 crore in Q4 FY25.

North America contributed to 42% of its revenue mix in the January-March 2025 quarter, followed by Europe (15%), India (15%) and emerging markets (16%).

The company's earnings before interest, tax, depreciation and amortisation (EBITDA) stood at ₹2,975 crore, jumping 58.9% YoY from ₹1,872 crore seen in the March quarter of FY24 (Q4FY24).

Dr Reddy's board recommends final dividend

Dr Reddy's Laboratories' board of directors recommended a final dividend of ₹8 per equity share of ₹1 each for the financial year 2024-25, subject to shareholder approval at the ensuing AGM.

The company set July 10, 2025, as the record date to determine the members eligible for the final dividend.

Shares of Dr Reddy's closed at ₹1,155.90 apiece, up 0.69% on the National Stock Exchange (NSE). The results were announced after the market hours.